|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 08, 2016 ) COPD is a chronic disease condition with a combination of symptoms of both chronic bronchitis and emphysema. Chronic bronchitis results in inflammation in the bronchioles, which results in increased mucus production. The condition is usually associated with a long-term cough with mucus. Emphysema results in the destruction of the walls of the alveoli, resulting in difficulty in breathing.
Publisher's analysts forecast the global chronic obstructive pulmonary disease (COPD) drugs market to grow at a CAGR of 4.85% during the period 2016-2020.
For more information about this report: http://www.reportsweb.com/global-chronic-obstructive-pulmonary-disease-drugs-market-2016-2020
Covered in this report
The report covers the present scenario and the growth prospects of the global chronic obstructive pulmonary disease (COPD) drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used to treat COPD.
The market is divided into the following segments based on geography:
-Americas
-APAC
-EMEA
Publisher's report, Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
-AstraZeneca
-Boehringer Ingelheim
-GSK
-Merck
-Novartis
-Teva
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001332793/sample
Other prominent vendors
-Ache Laboratorios Farmaceuticos
-Almirall
-Aquinox Pharmaceuticals
-Ario Pharma
-Asmacure
-Astellas Pharma
-BioMarck Pharmaceuticals
-Chiesi Farmaceutici
-Cytokinetics
-F. Hoffmann-La Roche
-Gilead Sciences
-Innoviva
-Invion
-MediciNova
-Mereo BioPharma
-Mylan
-Orion Corporation
-Palobiofarma
-Pearl Therapeutics
-Pharmaxis
-Prosonix
-Pulmagen Therapeutics
-RespiVert
-SolAeroMed
-Sunovion Pharmaceuticals
-Theravance Biopharma
-Theron Pharmaceuticals
-Verona Pharma
-Xention
-Yungjin Pharm
-ZAI Lab
Market driver
-Uptake of LABA/LAMA combination therapies
-For a full, detailed list, view our report
Market challenge
-Negligence toward use of controller medications
-For a full, detailed list, view our report
Market trend
-Increased adoption of e-cigarettes and smoking cessation products
-For a full, detailed list, view our report
Inquire for Report at http://www.reportsweb.com/inquiry&RW0001332793/buying
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
